Shandong Jincheng Pharmaceutical Group Co., Ltd

Shandong Jincheng Pharmaceutical Group Co., Ltd, listed on the Shenzhen Stock Exchange in 2011, is a manufacturing company specializing in the petroleum, chemicals, and biomedicine sectors. The company operates across various fields, including pharmaceuticals, chemical engineering, synthetic biology, women's health, and high-end anti-infection products. It has also expanded into the new tobacco sector, establishing a strategic layout that encompasses five key pillars. The company's main business lines include the production of cephalosporin side chain active esters, biopharmaceuticals, specialty raw materials, and terminal formulations that cover a wide range of therapeutic areas. Shandong Jincheng boasts significant industry and scale advantages in pharmaceutical manufacturing, with a diversified model that emphasizes cephalosporin intermediates and bio-specialty materials. It operates nine modern production bases across major pharmaceutical clusters, ensuring comprehensive production capabilities. The company emphasizes safety and environmental protection while fostering strong brand and cultural advantages, enabling it to build long-term partnerships with major pharmaceutical firms.

1.The company boasts strong R&D advantages with platforms like a national enterprise technology center and key labs, and multiple subsidiaries as national high-tech enterprises. It emphasizes both independent R&D and external collaboration with universities, optimizing resources and building a three-level innovation system integrating independent, cooperative, and investment innovation. 2.The company holds significant advantages in industry and scale within pharmaceutical manufacturing and the health sector. Its diversified business model, centered on cephalosporin intermediates and bio-specialty materials, spans various therapeutic areas and dosage forms, with top domestic market shares in key intermediates like cephalosporins and glutathione. Strategically, the company operates nine modern production bases across major pharmaceutical clusters, boasting comprehensive production lines and workshops for APIs, intermediates, fermentation, and formulations. 3.The company possesses strong production and operational advantages. It has enhanced capabilities through continuous GMP, lean management, and EHS compliance, adopting a sales-centric approach with rigorous operational processes. This has built robust manufacturing and supply chain strengths. Supported by an experienced management team and a skilled workforce, the company excels in production conversion, scale, and industrialization. Accumulated experience across the entire value chain from R&D to sales further solidifies its competitive edge in operational management. 4.The company prioritizes safety and environmental protection. It enhances safety through automation and intelligent transformation, aiming for standardized management, reduced risks, and improved working conditions. Environmentally, it adopts a green development approach focusing on resource saving, emission reduction, and efficiency, upgrading systems like wastewater treatment and solvent recovery. 5.The company leverages strong brand and cultural advantages. It prioritizes brand building and operates with integrity, supported by a clear corporate culture, vision, and values. Customer-centric, it offers comprehensive solutions and fast, precise service. These strengths, combined with efficient operations and stable quality, have fostered long-term partnerships with major pharmaceutical firms like Kelun, Qilu, Lizhu, and Lvye Pharmaceutical.